ISB News

Glioblastoma tumor slice and corresponding density map

Looking at Tumors Through a New Lens

To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.

CRI iAtlas

CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.

New Method to Detect, Analyze Rare T Cells Another Step Toward Personalized Cancer Vaccines

Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.

Ozy’s ‘Future of X’ Podcast Features Drs. Jim Heath, Lee Hood

ISB President Dr. Jim Heath and ISB Co-founder Dr. Lee Hood are prominently featured in a new podcast created by Ozy, the popular news website. The podcast is called “The Future of X.” In the series’ first episode, Heath and Hood discuss cancer immunotherapy, personalized health care, and more.

ISB President Dr. Jim Heath

ISB President Dr. Jim Heath Awarded $750,000 from Andy Hill Cancer Research Endowment

The Andy Hill Cancer Research Endowment (CARE) announced $750,000 in grant funding for Dr. Jim Heath’s work on proactive cancer immunotherapies for initial and recurrent disease. This is the first stage of a planned longer program led by Jim and ISB, and involving Swedish Cancer Institute, Earl A. Chiles Research Institute in Portland, and UW Medicine.

CRI iAtlas

CRI, ISB, Sage Bionetworks Unveil Comprehensive Immunotherapy Tool

Three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics announced the release of the Cancer Research Institute iAtlas, a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.